The novel erythropoetic protein darbepoetin alfa exhibits enhanced biological activity and increased serum half-life compared with other erythropoetic agents used to treat chemotherapy-related anemia.
BARCELONA, Spain -- Sept. 26, 2007--Amgen today announced data from a Phase 2, randomized, multicenter, open-label study that suggest extended dosing of Aranesp(R) (darbepoetin alfa) paired with ...
THOUSAND OAKS, Calif., Jan. 16, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced top-line results of the Phase 3 Aranesp® (darbepoetin alfa) RED-HF® (Reduction of Events With Darbepoetin Alfa ...
This leaflet answers some common questions about Aranesp (darbepoetin alfa). It does not contain all the available information. It does not take the place of talking to your doctor, nurse or ...
Does one person provide it all? Defining the social support of women with cancer Pts with adverse events - n (%) 46 (79) 49 (88) 95 (83) Pts with serious adverse events - n (%) 18 (31) 21 (38) 39 (34) ...
BASEL, Switzerland, October 29 /PRNewswire/ -- A new study on pain published today has found that subcutaneous (SC) injections of the new renal anaemia therapy MIRCERA is associated with significantly ...
ORLANDO, Fla., (May 15, 2005) – Amgen Inc., (NASDAQ: AMGN) the world's largest biotechnology company, today announced that final results of a Phase 3 randomized, head-to-head study demonstrated that ...
NEW YORK, April 19 (Reuters) - Amgen Inc.'s. anemia drug Aranesp showed no increased risk of death compared to a placebo in a study of small-cell lung cancer patients undergoing chemotherapy, sending ...
A new study published in the Journal of Perinatology is helping premature babies avoid blood transfusions, thanks to new research and collaboration between researchers at Intermountain Health in Salt ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback